Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

Part of paid clinical trials in Kenosha, Wisconsin.

Sponsor
Glaukos Corporation
Study ID
NCT07400926
Status
Recruiting
Apply to this trial

Conditions

  • Ocular Hypertension (OH)
  • Open Angle Glaucoma (OAG)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Travoprost — COMBINATION_PRODUCT
    Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)

Study Details

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

Key Dates

First listed
Feb 10, 2026
Start date
Dec 17, 2025
Status verified
Feb 2026
Primary completion
Jun 30, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Model G2-TRIO
    Subjects receive a Travoprost intracameral implant with the Model G2-TRIO

Primary Outcome Measure

Successful implantation [ Time Frame: 1 day ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Glaukos Investigative SiteKenoshaWisconsin53140-

Find similar trials in Kenosha, WI

By research site
Glaukos Investigative Site· Kenosha, WI

Related Studies